| Research objectivesA retrospective study is conducted in clinical research to compare and analyze the TCM symptoms, tumor markers and the foci of those liver cancer patients who never had a surgery or those who had metastatic recurrence but survived with tumor, to evaluate the curative effect and validate the effectiveness of cancerous toxin and Xiaoai Jiedu prescription in treatment of liver cancer thus providing clinical evidence for its TCM treatment. The experimental study is mainly to observe the impacts that the drug-containing serum of Xiaoai Jiedu prescription has on the expression of hsa-miR-21-5p, hsa-miR-148a-3p in human liver cancer cells SMMC-7721, and to discuss the anti-tumor mechanisms of Xiaoai Jiedu prescription thus offering theoretical basis to its clinical application. The ultimate goal is to improve TCM treatment of liver cancer.Research MethodsThe retrospective study was conducted in clinical observation to gather the information of those liver cancer patients whose case conformed to the standards in clinical observation. We compared the changes that happened to the tumor markers and the foci one month or three months after TCM treatment, and the changes in TCM symptoms and in the weight of the patients three months after the treatment. The ultimate goal is to evaluate the efficacy of Xiaoai Jiedu prescription.In the experimental study, HepG2 cells were divided into model group, DDP group and Xiaoai Jiedu prescription groups of high-, mid-and low-dosage. We added into them relevant nutrient solutions respectively and determinated the content of hsa-miR-21-5p and hsa-miR-148a-3p by real-time quantitative PCR after 24h action of the drug to observe the effects that drug-containing serum of Xiaoai Jiedu prescription has on the content of the two miRNA.SPSS 20.0 was applied in the statistical analysis.Research resultsIn clinical observation, the evaluation of the efficacy of TCM symptoms was conducted one month after the follow up finished by the 20 patients, of which 11 effective,8 successful,1 non-effective and 1 dead. Three months after the treatment,12 patients were checked, of them 1 with PR,8with SD,2 with PD and 1 dead. Six months after the treatment,11 patients were checked:1 with PR,6 with SD,2 with PD,1 dead. By comparing the level of the patients’tumor marker s, no obvious increase or decrease of it was found in the patients who checked one month and three months later compared to before the treatment. Three months after the treatment, the AFP mean of the tumor markers in patients with PR and SD was lower than before, no changes in CEA and the ferritin mean, and there were no statistical changes(P>0.05) in all the three of them. Three months after the treatment, some symptoms such as flatulence, much expectoration, depression, castalgia, tongue purple or with ecchymosis were improved, which was statistically significant(P<0.05). No obvious changes in the weight of the patients were found. In the experimental study, the expression of hsa-miR-21-5p was obviously lower in the group of high-dosage TCM and the one of DDP than that in the model group (P<0.05 in the high-dosage TCM group, P<0.01 in the DDP group). The expression of hsa-miR-148a-3p was significantly up regulated in the group of high-dosage TCM and the one of DDP than in the model group.Research conclusions1. The application of Xiaoai Jiedu prescription under the guidance of cancerous toxin can improve the clinical symptoms of advanced HCC (hepatic cellular cancer).2. The expression of hsa-miR-21-5p is higher in hepatoma cell. The drug-containing serum of Xiaoai Jiedu prescription can inhibit the growth of the hepatoma cell by down regulating hsa-miR-21-5p thus functioning in anti-tumor.3. The expression of hsa-miR-148a-3p is lower in hepatoma cell. The drug-containing serum of Xiaoai Jiedu prescription can inhibit the growth of the hepatoma cell by up regulating hsa-miR-148a-3p thus functioning in anti-tumor. |
PDF Full Text Request